Medicine and Dentistry
Myelofibrosis
100%
Ruxolitinib
100%
Body Weight
28%
Symptom
28%
Myeloproliferative Neoplasm
28%
Disease
14%
Quality of Life
14%
Adverse Event
14%
Randomized Controlled Trial
14%
Kinase Signaling
14%
Constitutional Symptoms
14%
Splenomegaly
14%
Symptom Assessment
14%
Janus Kinase Inhibitor
14%
Leukemia
14%
Janus Kinase
14%
Extramedullary Hematopoiesis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Myelofibrosis
100%
Ruxolitinib
100%
Symptom
57%
Myeloproliferative Neoplasm
28%
Adverse Event
14%
Leukemia
14%
Randomized Controlled Trial
14%
Disease
14%
Janus Kinase
14%
Splenomegaly
14%
Janus Kinase Inhibitor
14%
Biochemistry, Genetics and Molecular Biology
Ruxolitinib
100%
Body Weight
28%
Randomized Controlled Trial
14%
Extramedullary Hematopoiesis
14%
Janus Kinase
14%
Janus Kinase Inhibitor
14%
Immunology and Microbiology
Body Weight
100%
Extramedullary Hematopoiesis
50%